Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.
Kumada N, Nakane K, Yamada T, Tomioka-Inagawa R, Sugino F, Namiki S, Kawase M, Kawase K, Takeuchi S, Nakai C, Kato D, Takai M, Iinuma K, Tobisawa Y, Koie T. Kumada N, et al. Among authors: takeuchi s. Minim Invasive Ther Allied Technol. 2023 Dec;32(6):307-313. doi: 10.1080/13645706.2023.2249986. Epub 2023 Aug 22. Minim Invasive Ther Allied Technol. 2023. PMID: 37607213 Review.
Validation of standardized training system for robot-assisted radical prostatectomy: comparison of perioperative and surgical outcomes between experienced surgeons and novice surgeons at a low-volume institute in Japan.
Kato D, Namiki S, Ueda S, Takeuchi Y, Takeuchi S, Kawase M, Kawase K, Nakai C, Takai M, Iinuma K, Nakane K, Koie T. Kato D, et al. Among authors: takeuchi s, takeuchi y. Minim Invasive Ther Allied Technol. 2022 Oct;31(7):1103-1111. doi: 10.1080/13645706.2022.2056707. Epub 2022 Mar 30. Minim Invasive Ther Allied Technol. 2022. PMID: 35352619
The Utility of Combined Target and Systematic Prostate Biopsies in the Diagnosis of Clinically Significant Prostate Cancer Using Prostate Imaging Reporting and Data System Version 2 Based on Biparametric Magnetic Resonance Imaging.
Kato D, Ozawa K, Takeuchi S, Kawase M, Kawase K, Nakai C, Takai M, Iinuma K, Nakane K, Kato H, Matsuo M, Suzui N, Miyazaki T, Koie T. Kato D, et al. Among authors: takeuchi s. Curr Oncol. 2021 Mar 22;28(2):1294-1301. doi: 10.3390/curroncol28020123. Curr Oncol. 2021. PMID: 33809967 Free PMC article.
A Case of Localized Prostate Cancer Associated with Polymyalgia Rheumatica with Marked Symptomatic Improvement after Robot-Assisted Radical Prostatectomy.
Kawase M, Nakane K, Namiki S, Takeuchi Y, Ueda S, Kawase K, Nakai C, Takeuchi S, Kato D, Takai M, Iinuma K, Fuwa M, Saigo C, Miyazaki T, Morita H, Koie T. Kawase M, et al. Among authors: takeuchi s, takeuchi y. Case Rep Urol. 2021 Oct 15;2021:8026883. doi: 10.1155/2021/8026883. eCollection 2021. Case Rep Urol. 2021. PMID: 34691800 Free PMC article.
[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S, Nakane K, Namiki S, Takeuchi Y, Kawase M, Takeuchi S, Kawase K, Nakai C, Kato D, Takai M, Iinuma K, Tsuchiya T, Miyazaki T, Koie T. Ueda S, et al. Among authors: takeuchi s, takeuchi y. Hinyokika Kiyo. 2022 May;68(5):139-143. doi: 10.14989/ActaUrolJap_68_5_139. Hinyokika Kiyo. 2022. PMID: 35748231 Free article. Japanese.
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma.
Tomioka-Inagawa R, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, Kawase M, Kawase K, Kato D, Takai M, Iinuma K, Yokoi S, Nakano M, Koie T. Tomioka-Inagawa R, et al. Among authors: takeuchi s. Biomedicines. 2022 Jul 6;10(7):1609. doi: 10.3390/biomedicines10071609. Biomedicines. 2022. PMID: 35884914 Free PMC article.
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.
Yamada T, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, Kawase M, Kawase K, Kato D, Takai M, Iinuma K, Yokoi S, Nakano M, Koie T. Yamada T, et al. Among authors: takeuchi s. Biomedicines. 2022 Sep 9;10(9):2243. doi: 10.3390/biomedicines10092243. Biomedicines. 2022. PMID: 36140344 Free PMC article.
Effectiveness and Safety of Molecular-Targeted Therapy after Nivolumab Plus Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.
Iinuma K, Kameyama K, Taniguchi T, Kawada K, Ishida T, Takagi K, Nagai S, Enomoto T, Tomioka M, Kawase M, Takeuchi S, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: takeuchi s. Cancers (Basel). 2022 Sep 21;14(19):4579. doi: 10.3390/cancers14194579. Cancers (Basel). 2022. PMID: 36230501 Free PMC article.
2,925 results